GlassScriptPhysician profile
Bradford Chervin
NPI 1033215256
$1,783.57
in general payments reported to CMS, 2019-2025
15 companies · $831 in 2025
The $831 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $44.43 · 2021: $180 · 2022: $246 · 2023: $162 · 2024: $181 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.24 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $699.14 | 2021-2025 | Dupixent |
| Genzyme Corporation | $289.07 | 2021-2025 | |
| Smith+Nephew, INC. | $143.16 | 2019-2020 | |
| Medtronic, INC. | $140.15 | 2025 | Pteye Parathyroid Detection System, Stealthstation S8 Platform |
| Glaxosmithkline, LLC. | $137.66 | 2025 | Nucala |
| Intersect Ent, INC. | $80.63 | 2021 | |
| Amgen INC. | $56.59 | 2025 | Tezspire |
| Acclarent, INC | $51.85 | 2022 | |
| Stryker Corporation | $47.16 | 2025 | Xpress Loprofile |
| Aerin Medical INC. | $32.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.14 | 2025 | Tezspire |
| Arbor Pharmaceuticals, INC. | $23.59 | 2020 | |
| Merck Sharp & Dohme LLC | $20.67 | 2025 | Keytruda |
| Halozyme INC | $18.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradford Chervin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.